Clinical trial
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765
NCT00205465 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00205465 |
|---|---|
| Title | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | VX-765 |
| Enrollment | 64 |
| Start date | Dec 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 5, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: